These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Targeted Therapies in Chronic Lymphocytic Leukemia: Is 2 (or 3) Better Than 1? Ujjani C; Cheson BD Cancer J; 2019; 25(6):449-454. PubMed ID: 31764127 [TBL] [Abstract][Full Text] [Related]
10. Mechanisms of ibrutinib resistance in chronic lymphocytic leukemia and alternative treatment strategies. Lama TG; Kyung D; O'Brien S Expert Rev Hematol; 2020 Aug; 13(8):871-883. PubMed ID: 32673127 [TBL] [Abstract][Full Text] [Related]
11. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia. Maddocks K; Jones JA Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703 [TBL] [Abstract][Full Text] [Related]
12. Update on signal inhibitors in chronic lymphocytic leukemia. Boddu P; Jain N Clin Adv Hematol Oncol; 2018 Apr; 16(4):279-288. PubMed ID: 29742083 [TBL] [Abstract][Full Text] [Related]
13. How to Choose the Best Treatment and Testing for Chronic Lymphocytic Leukemia in the Tsunami of New Treatment Options. Yeung CCS; Shadman M Curr Oncol Rep; 2019 Jul; 21(8):74. PubMed ID: 31327069 [TBL] [Abstract][Full Text] [Related]
14. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia. Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653 [TBL] [Abstract][Full Text] [Related]
15. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future? Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240 [TBL] [Abstract][Full Text] [Related]
16. Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy. Nikolaenko L; Liu T; Danilov AV Expert Rev Anticancer Ther; 2021 May; 21(5):481-488. PubMed ID: 33499685 [No Abstract] [Full Text] [Related]
17. Infections in patients with chronic lymphocytic leukaemia: Mitigating risk in the era of targeted therapies. Teh BW; Tam CS; Handunnetti S; Worth LJ; Slavin MA Blood Rev; 2018 Nov; 32(6):499-507. PubMed ID: 29709246 [TBL] [Abstract][Full Text] [Related]
18. Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. Arnason JE; Brown JR Curr Oncol Rep; 2017 Sep; 19(9):61. PubMed ID: 28755313 [TBL] [Abstract][Full Text] [Related]
19. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia. Eradat H Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151 [TBL] [Abstract][Full Text] [Related]
20. The magnitude of improvement in progression-free survival with targeted therapy in relapsed/refractory chronic lymphocytic leukemia based on prognostic risk category: a systematic review and meta-analysis. Molica S; Giannarelli D; Mirabelli R; Levato L; Shanafelt TD Leuk Lymphoma; 2019 Jul; 60(7):1644-1649. PubMed ID: 30516079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]